Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17949037 | 1.00 | TSHR (0.47) | TSHRNPC1USP2ALDH1A1CYP2C9 | |
| SCHEMBL17949438 | 0.96 | TSHR (0.49) | TSHRNPC1USP2ALDH1A1CYP2C9 | |
| SCHEMBL29529765 | 0.96 | TSHR (0.49) | TSHRNPC1USP2ALDH1A1CYP2C9 | |
| SCHEMBL17949466 | 0.92 | RORC (0.42) | TSHRNPC1USP2ALDH1A1CYP2C9 | |
| SCHEMBL30833511 | 0.90 | TSHR (0.47) | TSHRNPC1USP2ALDH1A1CYP2C9 | |
| SCHEMBL17942474 | 0.90 | TSHR (0.47) | TSHRNPC1USP2ALDH1A1CYP2C9 | |
| SCHEMBL17949001 | 0.90 | TSHR (0.49) | TSHRNPC1USP2ALDH1A1CYP2C9 | |
| SCHEMBL17949141 | 0.86 | CYP3A4 (0.51) | TSHRNPC1USP2ALDH1A1CYP2C9 | |
| SCHEMBL17949164 | 0.83 | RORC (0.46) | RORC | |
| SCHEMBL17949459 | 0.83 | USP2 (0.46) | TSHRUSP2ALDH1A1CYP2C9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275952-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | MYOKARDIA INC (US) | 2025-09-04 | — | — | US | disclosed |
| US-20220117955-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | MyoKardia, Inc. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250275952-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | TNNI3, UMPS, TNNT2 | TSHR 3993/4885NPC1 2311/4885USP2 366/4885 |
| US-20220117955-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | TNNI3, UMPS, TNNT2 | TSHR 3993/4885NPC1 2311/4885USP2 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.